Fox Run Management L.L.C. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,137 shares of the company’s stock, valued at approximately $284,000.
Other large investors have also modified their holdings of the company. Valeo Financial Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $134,000. Rehmann Capital Advisory Group increased its holdings in shares of IDEXX Laboratories by 44.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 668 shares of the company’s stock worth $146,000 after acquiring an additional 207 shares during the period. Cerebellum GP LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $181,000. Financial Gravity Wealth Inc. acquired a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $191,000. Finally, TLP Group LLC increased its holdings in shares of IDEXX Laboratories by 52,750.0% in the 1st quarter. TLP Group LLC now owns 1,057 shares of the company’s stock worth $202,000 after acquiring an additional 1,055 shares during the period. 91.22% of the stock is currently owned by institutional investors.
A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $255.00 price objective on the stock in a report on Monday, June 18th. Piper Jaffray Companies increased their price objective on shares of IDEXX Laboratories to $236.00 and gave the stock an “overweight” rating in a report on Wednesday, August 1st. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. Credit Suisse Group increased their price objective on shares of IDEXX Laboratories from $228.00 to $231.00 and gave the stock an “outperform” rating in a report on Thursday, June 21st. Finally, Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $225.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, July 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Buy” and an average price target of $244.00.
IDXX stock opened at $222.42 on Friday. The company has a debt-to-equity ratio of -14.77, a quick ratio of 0.73 and a current ratio of 0.96. IDEXX Laboratories, Inc. has a fifty-two week low of $146.09 and a fifty-two week high of $256.22. The stock has a market capitalization of $21.62 billion, a P/E ratio of 67.81, a PEG ratio of 2.28 and a beta of 0.64.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Wednesday, August 1st. The company reported $1.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.06. The firm had revenue of $580.75 million for the quarter, compared to analysts’ expectations of $574.68 million. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. IDEXX Laboratories’s quarterly revenue was up 14.1% on a year-over-year basis. During the same quarter last year, the company earned $0.87 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 4.18 earnings per share for the current fiscal year.
In related news, Director Bruce L. Claflin bought 415 shares of the stock in a transaction on Friday, August 3rd. The shares were purchased at an average price of $242.12 per share, with a total value of $100,479.80. Following the purchase, the director now owns 1,415 shares in the company, valued at $342,599.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jonathan W. Ayers sold 7,000 shares of the firm’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $247.33, for a total transaction of $1,731,310.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 70,129 shares of company stock worth $17,159,219. 2.56% of the stock is owned by corporate insiders.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
See Also: What is a put option?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.